1147998-34-2

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Benzyl 4-(trimethylsilyloxy)-5,6-dihydropyridine-1(2H)-carboxylate is utilized as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its protective trimethylsilyloxy group allows for selective manipulation of the molecule during synthetic procedures, facilitating the creation of complex organic molecules with potential therapeutic or pesticidal properties.
Used in Medicinal Chemistry and Drug Development:
In the field of medicinal chemistry, benzyl 4-(trimethylsilyloxy)-5,6-dihydropyridine-1(2H)-carboxylate serves as a key component in the design and synthesis of new drug candidates. Its unique structure contributes to the development of molecules with specific biological activities, making it an important tool in drug discovery and optimization processes.
Used in the Production of Fine Chemicals:
Benzyl 4-(trimethylsilyloxy)-5,6-dihydropyridine-1(2H)-carboxylate is also employed in the manufacture of fine chemicals, which are high-purity chemical compounds used in various applications, including research, diagnostics, and the production of specialty products. Its role in these processes highlights its versatility and importance in the chemical industry.

Upstream product

• 75-77-4 chloro-trimethyl-silane 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 6099-86-1 cyclohexylmethyl chlorocarbonate 

Downstream Products

• 913574-95-5 benzyl cis-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 955029-44-4 (syn)-3-fluoro-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 
• 847041-34-3 benzyl (3R,4S)-4-[{[(2S)-2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-(2,5-difluorophenyl)-2-phenyl-2,5-dihydro-1H-pyrrol-1-yl]carbonyl}(methyl)amino]-3-fluoropiperidine-1-carboxylate 
• 845256-80-6 C₁₄H₁₉FN₂O₂ 
• 845256-61-3 benzyl (3R,4S)-4-[(tert-butoxycarbonyl)(methyl)amino]-3-fluoropiperidine-1-carboxylate 
• 847041-33-2 benzyl (3S,4R)-4-[(tert-butoxycarbonyl)(methyl)amino]-3-fluoropiperidine-1-carboxylate 
• 845256-78-2 (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoropiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide 
• 913574-95-5 benzyl cis-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 1610033-97-0 benzyl 4-((tert-butyldimethylsilyl)oxy)-3-fluoropiperidine-1-carboxylate 
• 1228631-27-3 benzyl 3-fluoro-4-hydroxypiperidine-1-carboxylate 

Relevant academic research and scientific papers

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly selective and potent GPR40 agonists with a dual mechanism of action, promoting both glucose-dependent insulin and incretin secretion. Employing strategies to increase polarity and the ratio of sp3/sp2 character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Dihydropyrazole GPR40 modulators

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

PYRROLIDINE GPR40 MODULATORS

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to novel spirocyclic piperidines according to Formula (I) which are inhibitors of fatty acid synthase (FAS), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

FATTY ACID SYNTHASE INHIBITORS

Disclosed are compounds having Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, m, and n are defined herein and methods of using the same.

1,4 DI SUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS

Therapeutic compounds are disclosed having the general formula (1) that are useful for the treatment of metabolic disorders, including type II diabetes.The compounds have activity as agonists of GPR1 19. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

Discovery of spiropiperidine-based potent and selective Orexin-2 receptor antagonists

To generate novel human Orexin-2 Receptor (OX2R) antagonists, a spiropiperidine based scaffold was designed and a SAR study was carried out. Compound 4f possessed the highest OX2R antagonistic activity with an IC 50 value of 3 nM with 450-fold selectivity against Orexin-1 Receptor (OX1R).

PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF

The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.

TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS

Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.